The immune plasticity of mesenchymal stromal cells from mice and men: concordances and discrepancies

Raphaelle Romieu-Mourez¹, Daniel L.Coutu¹, Jacques Galipeau²

1The Montreal Center for Experimental Therapeutics in Cancer, Jewish General Hospital, McGill University, Montreal, Quebec, Canada, ²Winship Cancer Institute of Emory University, Department of Hematology/Oncology and Pediatrics, Atlanta, GA

TABLE OF CONTENTS

1. Abstract

2. Introduction

3. Human versus mouse MSCs: isolation and comparison with fibroblasts

3.1. Isolation of human MSCs

3.2. Isolation of mouse MSCs

3.3. Comparison of MSCs and fibroblasts

4. Immune profile of naïve human and mouse MSCs

4.1. Expression of molecules involved in antigen presentation

4.2. Expression of chemokines, cytokines, and prostaglandin E2

4.3. Other immune molecules expressed by MSCs

4.4. In vivo effects of MSCs in the absence of an ongoing immune or inflammatory response

5. Licensing of MSCs by inflammatory signals

5.1. Chemoattraction and adhesion to immune cells

5.2. Antigen processing

5.3. Immunosuppression

6. Immunosuppressive molecules produced by immune reaction-licensed MSCs : species differences or variations with methodology?

6.1. Characteristics of MSCs and immune cell co-cultures

6.2. PGE2 is upregulated by IFN-g and/or TNF-a in human and mouse MSCs

6.3. Nitric oxide versus indoleamine 2,3-dioxygenase production by mouse and human MSCs

6.4. Other immune suppressive factors induced by IFN-g and/or TNF-a in MSCs

7. Comparing human and mouse MSCs efficacy in GVHD clinical trials and mouse models

7.1. MSC-based GVHD clinical trials

7.2. Efficacy of MSCs in mouse models of GVHD

8. From mouse models to human studies: MSC effects in rheumatoid arthritis? 9. Summary 10. Acknowledgments

11. References

1. ABSTRACT